


Contents

Editors	x
Contributors	xiv
Reviewers	xx
Abbreviations	xxii
Acknowledgements	xxxii
Preface	xxxiii
Dedication	xxxv

Section 1: Molecular Targets

1	Introduction	1
2	Molecular Techniques in Precision Oncology	9
	Precision Oncology	9
	Tissue Types and Preparation	11
	Molecular Methods in Clinical Practice	14
	Pitfalls and Limitations	16
	Further Reading	17
3	Hallmarks of Cancer	19
	The Hallmarks of Cancer	19
	1) Sustaining Proliferative Potential	22
	2) Evading Growth Suppressors	24
	3) Resisting Cell Death	25
	4) Enabling Replicative Immortality	26
	5) Inducing Angiogenesis	27
	6) Activating Invasion and Metastasis	29
	7) Deregulating Cellular Energetics	30
	8) Avoiding Immune Destruction	32

	9) Unlocking Phenotypic Plasticity	33
	10) Non-mutational Epigenetic Reprogramming	33
	11) Polymorphic Microbiomes	34
	12) Senescent Cells	34
	Closing Remarks and Future Research	35
	Further Reading	37
4	Molecular Pathways	39
	MAPK Pathway	39
	The PI3K Pathway	45
	Other Signalling Pathways	49
	Further Reading	49
5	Targeted T Cell Therapies for Solid Tumours	51
	TCR-engineered T Cells	52
	CAR-T Cells	56
	Toxicity of Targeted T Cell Therapies	58
	Conclusion	59
	Further Reading	59
6	Hormonal Targets	61
	NR Superfamily	61
	NR Family 1A – TRs	63
	NR Family 1B – RARs	63
	NR Family 3A and 3C – ER, PgR and AR	65
	IGF-1R and IR	67
	Further Reading	68
7	Gene Fusions	70
	Gene Fusion Testing in Clinical Practice	71
	Approved Targeted Therapies in Gene Fusion-positive Solid Tumours	73
	Conclusion	77
	Further Reading	77
8	Molecular Markers in Clinical Practice	80
	Molecular Markers in Daily Practice: How to Use Them	81
	Molecular Alterations with Matching Targeted Drugs	85

Conclusion	99
Further Reading	100
9 Molecular Markers in (Early-Phase) Clinical Trials	102
Targeting Kinases	102
Targeting Phosphatases	105
Widening the Diagnostic Net to Capture Genomic Predictors of Response	106
DNA Damage Response	108
Targeting the Guardian of the Genome	112
Further Reading	114
 Section 2 : Targeted Therapies in Specific Disease Groups	
10 Thoracic Malignancies	119
Targeting <i>EGFR</i> Mutations	119
Targeting <i>ALK</i> Translocation	121
Targeting the Uncommon Mutations	123
Targeting PD-(L)1 and CTLA-4	124
Future Directions	125
Conclusion	126
Further Reading	130
11 Breast Cancer	131
Luminal Breast Cancer	131
Triple-negative Breast Cancer	133
HER2-positive Breast Cancer	136
HER2-low Breast Cancer	138
Conclusions	139
Further Reading	141
12 Gastrointestinal Malignancies	144
Colorectal Cancer	144
Gastric and Oesophageal Tumours	148
Hepatocellular Carcinoma	150
Conclusions	153
Further Reading	153

13	Genitourinary Malignancies	158
	Renal Cell Cancer (RCC): A Prime Example for Targeted Therapies	159
	Urothelial Cancer: Molecular Targets and Treatments	162
	Prostate Cancer (PC)	165
	Conclusion	171
	Further Reading	171
14	Melanoma	174
	The MAPK Pathway and Associated Mutations	174
	Combined BRAF/MEK Inhibition	175
	KIT Inhibition	180
	Tebentafusp	181
	Potential Future Developments	181
	Conclusion	184
	Further Reading	184
15	Head & Neck Tumours	187
	Treatment Strategy in Each Tumour Type	187
	LA-HNSCC	188
	R/M HNSCC	188
	Clinical Trials	189
	Potential Future Developments	189
	Conclusion	192
	Further Reading	192
16	Haematological Malignancies	194
	Recent Advances in Mature B-Cell Neoplasms	194
	Acute Myeloid Leukaemia	198
	Multiple Myeloma	200
	Potential Future Developments	203
	Conclusion	203
	Further Reading	203
17	Gynaecological Malignancies	206
	Ovarian Cancer	206
	Cervical Cancer	211
	Endometrial Cancer	213

Future Developments	214
Conclusion	216
Further Reading	216
18 Mesenchymal Tumours	219
Treatment Strategy	220
Potential Future Developments	230
Further Reading	230
19 Central Nervous System Malignancies	233
Targeted Therapies in Primary CNS Malignancies	233
Neurotrophic Tyrosine Receptor Kinase (<i>NTRK</i>)	233
<i>BRAF</i>	234
Isocitrate Dehydrogenase (<i>IDH</i>)	234
Conclusion	236
Further Reading	236
20 Toxicity Management	238
Skin Toxicity	238
Drug-induced Pneumonitis/Interstitial Lung Disease	242
Cardiovascular Toxicity	243
Ocular Toxicity	246
Gastrointestinal/Hepatobiliary Toxicity	246
Endocrine/Metabolic Toxicity	248
Haematological Toxicity	249
Neurotoxicity and Musculoskeletal Toxicity	250
Further Reading	260
Index	262

Does this Table of Contents interest you? Would you like to read more?

If you are an ESMO Member, simply log in to your account to download the complete book along with over 20 other titles on a broad range of topics - all of them written to assist you in your daily practice.

If not an ESMO Member, then consider joining!

ESMO Members belong to a global community of over 25,000 oncology professionals. Membership provides you many other benefits, including:

- **Full access to ESMO educational and scientific resources**, all centralised on our portal OncologyPRO
- An **online subscription to Annals of Oncology**
- A wide range of **exclusive courses and learning opportunities** for every stage of your career
- **Reduced registration fees** for ESMO meetings

Discover more and join ESMO today!